36 Recruiting Studies Using Isatuximab
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Isatuximab
A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
📍 Cross Cancer Institute — Edmonton, Alberta
Multiple Myeloma
View Study & Checklist ➔Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
📍 Mount Sinai Hospital — New York, New York
Smoldering Plasma Cell Myeloma
View Study & Checklist ➔Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
📍 UCLA Site Number : 8400010 — Los Angeles, California
Plasma Cell Myeloma
View Study & Checklist ➔Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Blood Cancer
View Study & Checklist ➔A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
📍 Local Institution - 119 — Denver, Colorado
Multiple Myeloma
View Study & Checklist ➔Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance
📍 Massachusetts General Hospital, Renal Associates Clinic — Boston, Massachusetts
Monoclonal Gammopathy
View Study & Checklist ➔Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
📍 Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
Multiple Myeloma
View Study & Checklist ➔SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
📍 Mohtaseb Cancer Center and Blood Disorders Site Number : 8400028 — Bullhead City, Arizona
Plasma Cell Myeloma Recurrent
View Study & Checklist ➔Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
📍 OHSU Knight Cancer Institute — Portland, Oregon
Recurrent Plasma Cell Myeloma
View Study & Checklist ➔Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
📍 University of California — Orange, California
AL Amyloidosis
View Study & Checklist ➔Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
📍 The University of Alabama at Birmingham — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔KRDI in Transplant-Eligible MM
📍 Massachusetts General Hospital — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Recurrent Multiple Myeloma
View Study & Checklist ➔Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
📍 GSK Investigational Site — Atlanta, Georgia
Multiple Myeloma
View Study & Checklist ➔Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
📍 Karmanos Cancer Institute — Detroit, Michigan
Lymphoma
View Study & Checklist ➔Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
📍 Dana Farber Cancer Institute — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔Elimination of Minimal Residual Disease After Transplant
📍 Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
Multiple Myeloma
View Study & Checklist ➔Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
📍 GSK Investigational Site — Atlanta, Georgia
Multiple Myeloma
View Study & Checklist ➔A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
📍 Investigational Site Number: 8400006 — Fort Myers, Florida
Plasma Cell Myeloma
View Study & Checklist ➔Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
📍 Beth Israel Deaconess Medical Center (BIDMC) — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma
📍 Beth Israel Deaconess Medical Center (BIDMC) — Boston, Massachusetts
Newly Diagnosed Multiple Myeloma
View Study & Checklist ➔Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
📍 University of Illinois at Chicago — Chicago, Illinois
Multiple Myeloma
View Study & Checklist ➔A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
📍 Mayo Clinic in Arizona - Phoenix- Site Number : 8400058 — Phoenix, Arizona
Plasma Cell Myeloma Refractory
View Study & Checklist ➔Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
📍 Massachusetts General Hospital — Boston, Massachusetts
Relapsed Cancer
View Study & Checklist ➔Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
📍 University of Wisconsin — Madison, Wisconsin
Relapse Multiple Myeloma
View Study & Checklist ➔Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
📍 Research Site — Gilbert, Arizona
Newly Diagnosed Multiple Myeloma
View Study & Checklist ➔Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
📍 University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
Multiple Myeloma
View Study & Checklist ➔IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
📍 Valkyrie Clinical Trials — Los Angeles, California
NHL
View Study & Checklist ➔Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
📍 Winship Cancer Institute of Emory University- Site Number : 8400010 — Atlanta, Georgia
Plasma Cell Myeloma Refractory
View Study & Checklist ➔Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
📍 M D Anderson Cancer Center — Houston, Texas
Multiple Myeloma
View Study & Checklist ➔Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
📍 Cross Cancer Institute — Edmonton, Alberta
Multiple Myeloma
View Study & Checklist ➔Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
📍 Cross Cancer Institute — Edmonton, Alberta
Multiple Myeloma
View Study & Checklist ➔A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
📍 Scripps Clinic Torrey Pines — La Jolla, California
Multiple Myeloma
View Study & Checklist ➔ELISA in Relapsed/Refractory MM
📍 Massachusetts General Hospital — Boston, Massachusetts
Relapsed Refractory Multiple Myeloma (RRMM)
View Study & Checklist ➔Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
📍 Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
Multiple Myeloma
View Study & Checklist ➔Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
📍 Huntsman Cancer Institute at the University of Utah — Salt Lake City, Utah
Multiple Myeloma
View Study & Checklist ➔